Literature DB >> 23983954

Varenicline-induced psychotic depressive episode in a patient with bipolar disorder.

Bilge Burcak Annagur, Yasin Bez.   

Abstract

Varenicline is a relatively novel medication for smoking cessation. Increased neuropsychiatric symptoms have been reported with its use and it is listed among drugs with a black box warning. History of a psychiatric diagnosis is suggested to be a vulnerability factor for the development of some psychiatric side effects with its use. However, empirical evidence to support this point is very limited. Here, we report the case of a bipolar patient who developed a depressive episode with psychotic features immediately after varenicline use. Clinicians should be careful about the varenicline-induced neuropsychiatric effects. Healthcare professionals can provide an important role in helping to prevent and manage worsening psychiatric symptoms.

Entities:  

Keywords:  bipolar disorder; side effect; varenicline

Year:  2012        PMID: 23983954      PMCID: PMC3736926          DOI: 10.1177/2045125311430111

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  15 in total

1.  Varenicline-induced manic episode in a patient with bipolar disorder.

Authors:  Izchak Kohen; Neil Kremen
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

Review 2.  Smoking and suicide: a brief overview.

Authors:  John R Hughes
Journal:  Drug Alcohol Depend       Date:  2008-08-03       Impact factor: 4.492

3.  Varenicline gets stronger warnings about psychiatric problems, vehicle crashes.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2009-08-26       Impact factor: 56.272

Review 4.  A preliminary benefit-risk assessment of varenicline in smoking cessation.

Authors:  Kate Cahill; Lindsay Stead; Tim Lancaster
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression.

Authors:  Andres J Pumariega; Robert Nelson; Larry Rotenberg
Journal:  CNS Spectr       Date:  2008-06       Impact factor: 3.790

Review 6.  The role of dopamine in bipolar disorder.

Authors:  David A Cousins; Kelly Butts; Allan H Young
Journal:  Bipolar Disord       Date:  2009-12       Impact factor: 6.744

Review 7.  Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.

Authors:  Sharon M Hall; Judith J Prochaska
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

Review 8.  Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.

Authors:  N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

9.  Worsening psychosis induced by varenicline in a hospitalized psychiatric patient.

Authors:  Bethany A DiPaula; Michele D Thomas
Journal:  Pharmacotherapy       Date:  2009-07       Impact factor: 4.705

10.  Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

Authors:  D Gunnell; D Irvine; L Wise; C Davies; R M Martin
Journal:  BMJ       Date:  2009-10-01
View more
  1 in total

1.  Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study.

Authors:  Yasmina Molero; Paul Lichtenstein; Johan Zetterqvist; Clara Hellner Gumpert; Seena Fazel
Journal:  BMJ       Date:  2015-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.